Last $0.54 USD
Change Today -0.021 / -3.75%
Volume 79.7K
ACUR On Other Exchanges
As of 8:10 PM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

acura pharmaceuticals inc (ACUR) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/27/14 - $2.12
52 Week Low
12/2/14 - $0.41
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

acura pharmaceuticals inc (ACUR) Related Businessweek News

No Related Businessweek News Found

acura pharmaceuticals inc (ACUR) Details

Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, researches, develops, and commercializes products to address medication abuse and misuse utilizing its proprietary Aversion and Impede technologies. The company’s products include Oxecta tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed, a pseudoephedrine HCl tablet that is used as a nasal decongestant in various non-prescription and prescription cold, sinus, and allergy products. It has seven additional opioid products, including hydrocodone bitartrate/acetaminophen, methadone HCl, morphine sulfate, oxycodone HCl/acetaminophen, oxymorphone HCl, and tramadol HCl tablets utilizing Aversion technology in various stages of development. The company has a license, development, and commercialization agreement with King Pharmaceuticals Research and Development, Inc. to manufacture and commercialize Oxecta products in the United States, Canada, and Mexico. Acura Pharmaceuticals, Inc. was founded in 1935 and is based in Palatine, Illinois.

15 Employees
Last Reported Date: 03/3/14
Founded in 1935

acura pharmaceuticals inc (ACUR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $383.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $219.0K
Vice President of Technical Affairs
Total Annual Compensation: $282.0K
Vice President, Treasurer and Corporate Contr...
Total Annual Compensation: $170.0K
Vice President of Marketing
Total Annual Compensation: $155.0K
Compensation as of Fiscal Year 2013.

acura pharmaceuticals inc (ACUR) Key Developments

Acura Pharmaceuticals, Inc. - Special Call

To discuss the Agreement with Egalet on font-weight

Acura Pharmaceuticals, Inc. Partners with Egalet Corporation, Egalet US, Inc. and Egalet Ltd. to Commercialize Immediate Release Oxycodone Product Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology

Acura Pharmaceuticals, Inc. announced that the company has entered into a Collaboration and License Agreement with Egalet US, Inc. and Egalet Ltd. (together 'Egalet', subsidiaries of Egalet Corporation, which is also a party to the Agreement with obligations thereunder) granting Egalet exclusive worldwide rights to commercialize Acura's immediate release oxycodone hydrochloride tablets product which incorporates Acura's patented Aversion® (abuse-deterrent) Technology platform. The licensed product, formerly known as Oxecta, will be marketed by Egalet under the name OXAYDO. OXAYDO is FDA approved in 5mg and 7.5mg strengths for the treatment of acute and chronic moderate to severe pain. Acura and Egalet will form a joint steering committee to coordinate commercialization strategies and the development of product line extensions. Egalet will be responsible for all commercial, regulatory and manufacturing activities. The parties are working to transition the product to Egalet for commercial launch in the U.S. as soon as commercially practical. The Agreement provides for an upfront cash payment of $5.0 million to Acura upon execution, with an additional $2.5 million due upon the later of June 30, 2015 and the first commercial sale of the Product in the U.S.; but in no event later than January 1, 2016. Acura is to receive an additional one-time payment of $12.5 million when annual world-wide net sales of OXAYDO first reach $150 million in a calendar year. Acura is also to receive a stepped royalty at percentage rates from mid-single digits to double digits based on the level of OXAYDO world-wide net sales in a calendar year (including any product line extensions). Royalties will be payable on the first commercial sale of OXAYDO and expire, on a country-by-country basis, upon the expiration of Acura's patent in such country.

Acura Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Acura Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues, net of $145,000 against $83,000 a year ago. Operating loss was $2,646,000 against $3,225,000 a year ago. Loss before income taxes was $2,904,000 against $3,190,000 a year ago. Net loss was $2,904,000 against $3,190,000 a year ago. Basic and diluted loss per share was $0.06 against $0.07 a year ago. For the nine months, the company reported total revenues, net of $222,000 against $88,000 a year ago. Operating loss was $9,744,000 against $10,609,000 a year ago. Loss before income taxes was $10,513,000 against $10,484,000 a year ago. Net loss was $10,513,000 against $10,484,000 a year ago. Basic and diluted loss per share was $0.22 against $0.22 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACUR:US $0.54 USD -0.021

ACUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Durect Corp $0.93 USD +0.0098
Johnson & Johnson $101.48 USD -0.61
Perrigo Co PLC $153.51 USD -2.50
View Industry Companies

Industry Analysis


Industry Average

Valuation ACUR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 106.6x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACURA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at